TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
TriSalus Life Sciences, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 1/2Terminated
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
SD-101, Pembrolizumab
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
NCT05220722Enrollment23StartMar 2022Primary CompletionJul 2024CompletionJul 2024 - Phase 1Terminated
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
SD-101, Nivolumab
Metastatic Uveal Melanoma in the Liver
NCT04935229Enrollment67StartAug 2021Primary CompletionJul 2024CompletionJul 2024 - Phase 1Active, not recruiting
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
SD-101, anti-PD-1
Locally Advanced Pancreatic Adenocarcinoma
NCT05607953Enrollment60StartMar 2023Primary CompletionSep 2027est.CompletionOct 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1/2 | Terminated | SD-101, Pembrolizumab | NCT05220722 |
| Phase 1 | Terminated | SD-101, Nivolumab | NCT04935229 |
| Phase 1 | Active, not recruiting | SD-101, anti-PD-1 | NCT05607953 |